BCA BOA JA26-0618 redacted.pdf

Justification and Approval (J&A) for Other than Full and Open Competition

This J&A document, issued in October 2024 under Control Number JA26-0618, authorizes a sole source Basic Ordering Agreement (BOA) with an unnamed blood manufacturer for a three-year period (1 May 2026 – 30 April 2029) to procure Low Titer O Whole Blood (LTOWB) and liquid plasma supplies for the Defense Health Agency's Armed Services Blood Program Division (ASBPD). The action is justified under FAR Part 6.103-1(b), citing that only one responsible source exists. The base period runs 1 May 2026 – 30 April 2027, with two one-year option periods through 30 April 2029. Estimated values and specific pricing are redacted in the document. Funding is categorized as Operations & Maintenance (O&M).

The justification demonstrates that the selected contractor is the only large blood manufacturer in the United States capable of producing 35-day shelf-life LTOWB and 40-day liquid plasma to meet Department of Defense requirements for overseas contingency operations and large-scale combat operations (LSCO). Market research confirmed that only this single manufacturer produces these specific products with the required shelf life characteristics. The approval cites operational necessity stemming from recent Middle East engagements where existing blood supply sources proved inadequate, and notes that current world events require 3-4 times the blood requirements compared to previous surge operations. A sole source Notice of Intent (NOI) was posted to SAM.gov IAW FAR 5.101 for 15 days from 26 March 2026 to 10 April 2026. The contracting activity is the Defense Health Agency Contracting Activity (DHACA), Professional Services Contracting Division.